KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.95

Randomized controlled trial evaluating synbiotic supplementation as an adjuvant therapy in the treatment of Parkinson's disease.

Mohamed E Ramadan, Tarek M Mostafa, Azza A Ghali, Dalia R El-Afify

Inflammopharmacology 33(7) 3897-3908

PMID40434674
PMCIDPMC12354120
DOI10.1007/s10787-025-01752-8
发表日期2025-05-28
入排依据:The record is a randomized Phase III trial of a synbiotic supplement as adjunct to L-dopa therapy for Parkinson's disease, not a malignant neoplasm (oncology) trial. It lacks a primary or key secondary time-to-event efficacy endpoint (e.g., OS, PFS, DFS, HR, Kaplan-Meier); outcomes are symptom scores and biomarkers.
已检查 2 张 PubMed Figure,均未识别为 KM 图:Fig. 1:CONSORT/入组流程图;Fig. 2:AI 判定为 other。
摘要

摘要

BACKGROUND AND AIM: Neuroinflammatory mechanisms have been closely related to the microbiota-gut-brain axis and could lead to degeneration of dopaminergic neurons with subsequent development and progression of Parkinson's disease (PD). Targeting this pathway for the treatment of PD has sparked a lot of interest. Hence, this study investigates the therapeutic potential of a synbiotic supplement, in conjunction with L-dopa for the management of PD. METHODS: This randomized controlled trial enrolled 66 Parkinson's disease patients, who were randomly assigned to two groups: a control group (n = 33) receiving standard L-dopa/carbidopa (100/25 mg) therapy three times daily for three months, and a synbiotic group (n = 33) receiving the same L-dopa/carbidopa regimen with two sachets of the synbiotic supplement daily for three months. The outcome measures included assessment of Movement Disorder Society Unified Parkinson's Disease Rating Scale (MDS-UPDRS) and serum levels of tumor necrosis factor-alpha (TNF-α), malondialdehyde (MDA), brain-derived neurotrophic factor (BDNF), and α-synuclein (α-Syn). Blood samples were collected from all patients for biomarker analysis in serum. RESULTS: Three months after intervention, the synbiotic group demonstrated significantly greater improvement in motor and non-motor symptoms compared to the control group evidenced by the change in the scores of each part of the MDS-UPDRS. Concurrently, the synbiotic group exhibited significantly lower serum levels of pro-inflammatory marker TNF-α and oxidative stress marker MDA, and significantly higher levels of the neuroprotective factor BDNF. CONCLUSION: Supplementing with synbiotics exhibits promising neuroprotective and therapeutic effects in the treatment of Parkinson's disease patients. GOV REGISTRATION NUMBER: NCT05576818. Retrospectively registered in October 2022.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(2,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Fig. 1Fig. 1 CONSORT Participants flowchart
非 KM Figure
Fig. 2Fig. 2 a The change in serum level of TNF-α throughout the treatment course b The change in serum level of MDA throughout the treatment course c The change in serum level of BDNF throughout the treatment course d The change in serum level of α-Syn throughout the treatment course. TNF-α: tumor necrosis factor-alpha, MDA: malondialdehyde, BDNF: brain derived neurotrophic factor, α-Syn: α-synuclein protein. P1: difference between both groups after treatment. P2: difference between before and after treatment within the same group. Data are presented as median and interquartile range and analyzed using Mann Whitney U test to compare between the two groups, and Wilcoxon signed rank test to compare between before and after intervention within the same group. The dotted boxes represent data before treatment. The plain boxes represent data after treatment. The dashed brackets point to the difference between both groups after treatment. The solid brackets point to the difference between before and after treatment within the same group. * Statistical significance ( p < 0.05)
非 KM Figure